Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 3/20 | 0.54 |
| ▸ | GRB7 | Q14451 | 1/20 | 0.47 |
| ▸ | OXTR | P30559 | 3/20 | 0.47 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.47 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.47 |
| ▸ | SSTR4 | P31391 | 9/20 | 0.45 |
| ▸ | SSTR2 | P30874 | 8/20 | 0.45 |
| ▸ | SSTR3 | P32745 | 8/20 | 0.45 |
| ▸ | SSTR5 | P35346 | 8/20 | 0.45 |
| ▸ | SSTR1 | P30872 | 4/20 | 0.45 |
| ▸ | WDR5 | P61964 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17253461 | 0.97 | AVPR1B (0.52) | AVPR1BGRB7OXTRAVPR2AVPR1A | |
| SCHEMBL15511844 | 0.84 | AVPR1B (0.68) | AVPR1BGRB7OXTRAVPR2AVPR1A | |
| SCHEMBL15510980 | 0.74 | OXTR (0.70) | AVPR1BOXTRAVPR2AVPR1ASSTR4 | |
| SCHEMBL14060519 | 0.74 | OXTR (0.70) | AVPR1BOXTRAVPR2AVPR1ASSTR4 | |
| SCHEMBL324626 | 0.74 | OXTR (0.70) | AVPR1BOXTRAVPR2AVPR1ASSTR4 | |
| SCHEMBL13827825 | 0.74 | OXTR (0.70) | AVPR1BOXTRAVPR2AVPR1ASSTR4 | |
| SCHEMBL23114867 | 0.70 | OXTR (0.62) | AVPR1BOXTRAVPR2AVPR1A | |
| SCHEMBL29666839 | 0.68 | SSTR4 (0.51) | AVPR1BSSTR4SSTR2SSTR3SSTR5 | |
| SCHEMBL19560692 | 0.68 | OXTR (0.77) | AVPR1BGRB7OXTRAVPR2AVPR1A | |
| SCHEMBL22333523 | 0.64 | OXTR (0.68) | AVPR1BOXTRAVPR2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145058-A1 | METHOD FOR TARGETED CONJUGATION OF PEPTIDES AND PROTEINS BY PAIRED C2 BRIDGING OF CYSTEINE AMINO ACIDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-05-25 | — | — | US | disclosed |
| WO-2015169784-A1 | METHOD FOR TARGETED CONJUGATION OF PEPTIDES AND PROTEINS BY PAIRED C2 BRIDGING OF CYSTEINE AMINO ACIDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145058-A1 | METHOD FOR TARGETED CONJUGATION OF PEPTIDES AND PROTEINS BY PAIRED C2 BRIDGING OF CYSTEINE AMINO ACIDS | CSTB, BCAT1, PTMS | AVPR1B 2068/4885GRB7 1631/4885OXTR 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.